Arvinas, Inc. Signs Material Definitive Agreement

TL;DR

ARVN signed a big deal, details TBD.

AI Summary

On June 14, 2024, Arvinas, Inc. entered into a Material Definitive Agreement. The filing does not disclose specific details of the agreement, such as the counterparty or financial terms, but it signifies a significant development for the company.

Why It Matters

This filing indicates a significant new contract or partnership for Arvinas, Inc., which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and impact of the agreement.

Key Players & Entities

• Arvinas, Inc. (company) — Registrant

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share ARVN The Nasdaq Stock Market
• $14.95 million — greement, the Company made a payment of $14.95 million to Yale, comprising both an upfront pay
• $5.0 million — program. The Company will make another $5.0 million payment on the first anniversary of sig
• $15.0 million — Company will also pay to Yale (1) up to $15.0 million if it secures approval of the first and

Filing Documents

• arvn-20240614.htm (8-K) — 25KB
• 0001655759-24-000096.txt ( ) — 151KB
• arvn-20240614.xsd (EX-101.SCH) — 2KB
• arvn-20240614_lab.xml (EX-101.LAB) — 23KB
• arvn-20240614_pre.xml (EX-101.PRE) — 13KB
• arvn-20240614_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On June 14, 2024, Arvinas Operations, Inc. (the "Company"), a wholly owned, direct subsidiary of Arvinas, Inc., entered into an Amended and Restated License Agreement (the "Amended License Agreement") with Yale University ("Yale") pursuant to which the parties amended and restated the license agreement dated July 5, 2013, as amended on May 8, 2014, October 23, 2014, April 1, 2015, January 9, 2019 and June 3, 2019 (together, the "Original Agreement"). The effective date of the Amended License Agreement is June 18, 2024. In connection with the signing of the Amended License Agreement, the Company made a payment of $14.95 million to Yale, comprising both an upfront payment connected to the Amended License Agreement and an amount related to collaboration income under the Company's recently announced transaction with Novartis Pharma AG, involving the Company's product candidate ARV-766 and the Company's AR-V7 program. The Company will make another $5.0 million payment on the first anniversary of signing. Thereafter, the Company will also pay to Yale (1) up to $15.0 million if it secures approval of the first and second royalty products (as defined in the Amended License Agreement), (2) a low single digit percentage royalty on certain, more narrowly defined "collaboration products," and (3) a lower single digit royalty on its aggregate worldwide net sales of certain newly defined "meaningfully involved products." The Company's obligations under the Original Agreement to pay Yale minimum annual royalties and certain other annual fees have been eliminated and Yale has agreed to release all claims arising previously under the Original Agreement. Other provisions of the Original Agreement, including representations and warranties, annual license maintenance fees, specified development and regulatory milestones, indemnification and termination provisions, remain materially unchanged. The foregoing summary of the Amend

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARVINAS, INC. Date: June 18, 2024 By: /s/ Randy Teel Randy Teel Interim Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR